Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRIW) Common Equity (2020 - 2025)

Biofrontera has reported Common Equity over the past 6 years, most recently at $10.5 million for Q4 2025.

  • Quarterly results put Common Equity at $10.5 million for Q4 2025, up 136.41% from a year ago — trailing twelve months through Dec 2025 was $10.5 million (up 136.41% YoY), and the annual figure for FY2025 was $10.5 million, up 136.41%.
  • Common Equity for Q4 2025 was $10.5 million at Biofrontera, up from -$2.6 million in the prior quarter.
  • Over the last five years, Common Equity for BFRIW hit a ceiling of $23.9 million in Q4 2022 and a floor of -$17.4 million in Q3 2021.
  • Median Common Equity over the past 5 years was $5.2 million (2023), compared with a mean of $6.2 million.
  • Biggest five-year swings in Common Equity: skyrocketed 1359.72% in 2022 and later crashed 146.67% in 2025.
  • Biofrontera's Common Equity stood at $11.3 million in 2021, then skyrocketed by 110.6% to $23.9 million in 2022, then tumbled by 79.93% to $4.8 million in 2023, then fell by 7.51% to $4.4 million in 2024, then surged by 136.41% to $10.5 million in 2025.
  • The last three reported values for Common Equity were $10.5 million (Q4 2025), -$2.6 million (Q3 2025), and -$4.7 million (Q2 2025) per Business Quant data.